Economics of Respiratory Syncytial Virus (RSV) Vaccination in All U.S. Adults≥75 years-old, and Adults aged 60-74 and 50-59 years at Increased Risk : SUMMARY COMPARING MODELS FROM: GSK, Moderna AND University of Michigan-CDC

Details

• Personal Author:
  Ortega-Sanchez, Ismael R.
• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.)
• Description:
  Evidence to Recommendations Framework (EtR) : RSV Vaccination in Adults Aged 50–59 years, 60–74 years, and 75 years and older
• Subjects:
  Adult Cost-Benefit Analysis Respiratory Syncytial Virus Infections/prevention & Control Respiratory Syncytial Virus Vaccines/economics Risk Assessment
• Series:
  ACIP meeting Respiratory Syncytial Virus Vaccines – Adult
• Document Type:
  Presentation
• Name as Subject:
  ACIP meeting: 2024 June 26-28
• Genre:
  Conference Publications
• Place as Subject:
  United States
• Pages in Document:
  20 unnumbered slides
• Collection(s):
  Advisory Committee on Immunization Practices (ACIP)
• Main Document Checksum:
  urn:sha256:889151168cf2048cb308d5e939844d729d543760fbbbd3a7acea9d1d49e16f00
• Download URL:
  https://stacks.cdc.gov/view/cdc/157858/cdc_157858_DS1.pdf
• File Type:
  [PDF - 661.71 KB ]